Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Roblin

Showing results (91-100 of 252) with videos related to

Pageof 26
Sort By:
Journal of Crohn'S & Colitis|September 3, 2013
Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: a prospective multicenter cohort studyAbdenour Babouri, Xavier Roblin, Jérôme Filippi, et al.
Therapeutic Advances in Gastroenterology|February 13, 2023
Use of imaging modalities for decision-making in inflammatory bowel diseaseStéphane Nancey, Mathurin Fumery, Mathias Faure, et al.
Journal of Clinical Medicine|December 9, 2023
What Should We Know about Drug Levels and Therapeutic Drug Monitoring during Pregnancy and Breastfeeding in Inflammatory Bowel Disease under Biologic Therapy?Mathilde Barrau, Xavier Roblin, Leslie Andromaque, et al.
Journal of Gastroenterology and Hepatology|October 26, 2005
Primary ileal villous atrophy associated with microscopic colitisEmmanuel Germain, Xavier Roblin, Pierre-Emmanuel Colle, et al.
Virologie (Montrouge, France)|October 30, 2020
Cytomegalovirus and inflammatory bowel diseases, with a special focus on its role in ulcerative colitisAlexandre Jentzer, Nicolas Williet, Xavier Roblin, et al.
Inflammatory Bowel Diseases|May 5, 2018
Proactive Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel DiseaseXavier Roblin, Pauline Riviere, Mathurin Flamant, et al.
European Journal of Gastroenterology & Hepatology|December 1, 2007
Adjuvant chemotherapy for stage II colon cancer: influence of care structures' characteristics on a controversial clinical practiceEléonore Alter, Jean-Marc Phelip, Jean-Noel Guilhot, et al.
Gastroenterologie Clinique Et Biologique|March 27, 2003
[Exceptionally rapid hepatitis C virus clearance after blood exposure indicating probable hepatitis C virus re-infection]Xavier Roblin, Jean-Marc Phelip, Thierry Boudemaghe, et al.
Gastroenterologie Clinique Et Biologique|February 11, 2004
[Correction of insulin resistance syndrome does not cause normalisation of hyperferritinaemia]Xavier Roblin, Jean-Marc Phelip, Marie-Noëlle Hilleret, et al.
Journal of Market Access & Health Policy|April 29, 2016
Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn's disease patients who lose response to infliximabXavier Roblin, Alain Attar, Michel Lamure, et al.
Pageof 26

Showing results (91-100 of 252) with videos related to

Sort By:
Pageof 26
Journal of Crohn'S & Colitis|September 3, 2013
Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: a prospective multicenter cohort studyAbdenour Babouri, Xavier Roblin, Jérôme Filippi, et al.
Therapeutic Advances in Gastroenterology|February 13, 2023
Use of imaging modalities for decision-making in inflammatory bowel diseaseStéphane Nancey, Mathurin Fumery, Mathias Faure, et al.
Journal of Clinical Medicine|December 9, 2023
What Should We Know about Drug Levels and Therapeutic Drug Monitoring during Pregnancy and Breastfeeding in Inflammatory Bowel Disease under Biologic Therapy?Mathilde Barrau, Xavier Roblin, Leslie Andromaque, et al.
Journal of Gastroenterology and Hepatology|October 26, 2005
Primary ileal villous atrophy associated with microscopic colitisEmmanuel Germain, Xavier Roblin, Pierre-Emmanuel Colle, et al.
Virologie (Montrouge, France)|October 30, 2020
Cytomegalovirus and inflammatory bowel diseases, with a special focus on its role in ulcerative colitisAlexandre Jentzer, Nicolas Williet, Xavier Roblin, et al.
Inflammatory Bowel Diseases|May 5, 2018
Proactive Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel DiseaseXavier Roblin, Pauline Riviere, Mathurin Flamant, et al.
European Journal of Gastroenterology & Hepatology|December 1, 2007
Adjuvant chemotherapy for stage II colon cancer: influence of care structures' characteristics on a controversial clinical practiceEléonore Alter, Jean-Marc Phelip, Jean-Noel Guilhot, et al.
Gastroenterologie Clinique Et Biologique|March 27, 2003
[Exceptionally rapid hepatitis C virus clearance after blood exposure indicating probable hepatitis C virus re-infection]Xavier Roblin, Jean-Marc Phelip, Thierry Boudemaghe, et al.
Gastroenterologie Clinique Et Biologique|February 11, 2004
[Correction of insulin resistance syndrome does not cause normalisation of hyperferritinaemia]Xavier Roblin, Jean-Marc Phelip, Marie-Noëlle Hilleret, et al.
Journal of Market Access & Health Policy|April 29, 2016
Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn's disease patients who lose response to infliximabXavier Roblin, Alain Attar, Michel Lamure, et al.
Pageof 26